行情

REGN

REGN

再生元制药
NASDAQ

实时行情|Nasdaq Last Sale

350.78
+6.54
+1.90%
盘后: 350.78 0 0.00% 17:27 11/21 EST
开盘
343.60
昨收
344.24
最高
353.00
最低
341.61
成交量
85.44万
成交额
--
52周最高
442.00
52周最低
271.37
市值
385.14亿
市盈率(TTM)
19.27
分时
5日
1月
3月
1年
5年

分析师评级

23位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

REGN 新闻

  • Healthcare On The March
  • Seeking Alpha - Article.8小时前
  • Alnylam Pharmaceuticals Secures Its Second Approval, And The Pipeline Is Still Attractive
  • Seeking Alpha - Article.10小时前
  • Edited Transcript of REGN earnings conference call or presentation 5-Nov-19 1:30pm GMT
  • Thomson Reuters StreetEvents.1天前
  • The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Vertex Pharmaceuticals, Incyte and Regeneron Pharmaceuticals
  • Zacks.1天前

更多

所属板块

生物技术和医学研究
-0.31%
制药与医学研究
+0.32%

热门股票

名称
价格
涨跌幅

REGN 简况

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.
展开

Webull提供Regeneron Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。